TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12782954
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of metronidazole by mouth in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Study: 12782954
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to standard care (240 mg gentamicin IM and 100 mg doxycycline twice daily for 7 days)
Study: 12782954
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of metronidazole
Study: 10971246
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (Group 2)
Study: 8780763
Drug: Warmed local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed local anesthetic solution at 40 degrees C
Study: 8780763
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature local anesthetic solution
Study: 19710251
Drug: Daily inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhaled corticosteroid (ICS) medication adherence
Study: 12563673
Drug: Anti-TNF-alpha monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF-alpha monoclonal antibody
Study: 11289667
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of fecal anti‐lectin IgA antibodies and serum anti‐LC3 IgG antibodies
Study: 8422345
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil ethyl ester (K‐85, 5.7 g/day)
Study: 8422345
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of K‐85 and Lovastatin
Study: 3722962
Drug: Rifampin (RMP)
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (RMP) 900 mg once weekly for ten weeks
Study: 3722962
Drug: Regimen C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C: daily RMP 600 mg, ethionamide (ETH) 500 mg, and DDS or clofazimine (CLO) 100 mg for six months, followed by six months of daily DDS or CLO
Study: 3722962
Drug: Regimen D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D: identical to regimen C but comprising daily DDS or CLO plus ETH 500 mg during the second semester
Study: 3722962
Drug: Clofazimine (CLO)
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine (CLO) 100 mg daily
Study: 20375190
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg for children aged 2-11 months, 20 mg for children aged ≥12 months)
Study: 16360995
Drug: Non-steroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid anti-inflammatory (NSAIDs)
Study: 12610740
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice daily for 2.5 days
Study: 10622283
Drug: 3H-paroxetine binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3H-paroxetine binding after one year's treatment with different drugs
Study: 10622283
Drug: 3H-paroxetine binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3H-paroxetine binding before treatment
Study: 10622283
Drug: 3H-paroxetine binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3H-paroxetine binding after one year's treatment
Study: 7668493
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid administration, analgetics, avoidance of oral fluid or food intake in mild acute pancreatitis
Study: 7668493
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis in severe acute pancreatitis
Study: 7668493
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition in pancreatitis treatment
Study: 1719242
Drug: 2 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Study: 1719242
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Study: 7005780
Drug: High-dose naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naproxen (1250 mg/day for 5 days)
Study: 7005780
Drug: Low-dose naproxen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose naproxen (500 mg loading dose, then 750 mg/day for 5 days)
Study: 31603732
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) using two diode lasers with doses of 35.71 J/cm2 and 27.77 J/cm2, applied daily in contact and perpendicular to the skin.
Study: 27992691
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Study: 19092007
Drug: Buechel‐Pappas (BP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buechel‐Pappas (BP) implant
Study: 19092007
Drug: Scandinavian Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scandinavian Total Ankle Replacement (STAR) implant
Study: 19092007
Drug: Both BP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both BP and STAR implants
Study: 17295587
Drug: 42 mg
Normalized name: lithium 42 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 42 mg transdermal nicotine replacement (TNR)
Study: 17295587
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg transdermal nicotine replacement (TNR)
Study: 17295587
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg transdermal nicotine replacement (TNR)
Study: 10759625
Drug: ABT‐229 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐229 10 mg b.d.
Study: 10759625
Drug: ABT‐229 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐229 5 mg b.d.
Study: 8724443
Drug: Flunitrazepam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.50 mg
Study: 29273692
Drug: Highly-intensive practice
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly-intensive practice (4 hours daily)
Study: 29273692
Drug: Moderately-intensive practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately-intensive practice (2 hours daily)
Study: 27140929
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (4-week trial including 2-week placebo and 2-week treatment)
Study: 27140929
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (2-week treatment)
Study: 12240782
Drug: Lansoprazole granules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole granules in orange juice (180 mL)
Study: 12240782
Drug: Lansoprazole granules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole granules in tomato juice (180 mL)
Study: 12240782
Drug: Intact lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact lansoprazole capsule with water (180 mL)
Study: 10707109
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg) with diethylcarbamazine (DEC; 6 mg/kg)
Study: 10707109
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 micrograms/kg) with albendazole (400 mg)
Study: 10707109
Drug: DEC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (6 mg/kg) with albendazole (400 mg)
Study: 2248082
Drug: Moclobemide 100
Normalized name: moclobemide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 100 mg single dose
Study: 2248082
Drug: Moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 200 mg single dose
Study: 2248082
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg single dose
Study: 2248082
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg 3 times daily for 1 week
Study: 2248082
Drug: Moclobemide 100
Normalized name: moclobemide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 100 mg 3 times daily for 1 week
Study: 2248082
Drug: Moclobemide 200
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 200 mg 3 times daily for 1 week
Study: 2248082
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg 3 times daily for 1 week (24 hours after last dose)
Study: 2248082
Drug: Moclobemide 100
Normalized name: moclobemide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 100 mg 3 times daily in depressed patients
Study: 6446929
Drug: 2‐methyl histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐methyl histamine (H1‐receptor agonist)
Study: 6446929
Drug: Chlorpheniramine (H1‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (H1‐receptor antagonist)
Study: 6446929
Drug: Dimaprit (H2‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimaprit (H2‐receptor agonist)
Study: 30655038
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered at 2 hours after thrombolysis (Group A)
Study: 30655038
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered at 2-12 hours after thrombolysis (Group B)
Study: 30655038
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered at 12-24 hours after thrombolysis (Group C)
Study: 22802250
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (120 mg twice daily for 15 days)
Study: 22802250
Drug: Raltegravir alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir alone (400 mg)
Study: 15351864
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous unfractionated heparin (continuous infusion of 100 IU/kg/daily)
Study: 15351864
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (50 ml/daily as a continuous infusion)
Study: 15351864
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous unfractionated heparin
Study: 9727959
Drug: meta-chlorophenylpiperazine (MCPP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: meta-chlorophenylpiperazine (MCPP), 0.35 mg/kg
Study: 7984968
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b treatment (retreatment once or twice)
Study: 7984968
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b treatment
Study: 2531910
Drug: mesoglycan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty‐five days)
Study: 2531910
Drug: dexamethasone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone (24 mg/die i.v. for the first ten days)
Study: 392744
Drug: Acetard (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetard (controlled-release acetylsalicylic acid), 1 g X 4 or 2 g X 2 per day
Study: 392744
Drug: Magnecyl (instant-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnecyl (instant-release acetylsalicylic acid), 1 g X 4 daily
Study: 30318492
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg per day
Study: 23683841
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group CBT (eight, 2‐hour weekly sessions) plus individual dilemma‐focused therapy (eight, 1‐hour weekly sessions)
Study: 23683841
Drug: CBT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT alone (eight, 2‐hour group weekly sessions plus eight, 1‐hour individual weekly sessions)
Study: 18321497
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INHB and AMH
Study: 17298853
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² plus gemcitabine 1000 mg/m² i.v. on days 1 and 8 with intra-patient alternated dose escalation up to 100 and 1200 mg/m², respectively, over three cycles (arm A)
Study: 17298853
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m² followed by gemcitabine 1000 mg/m² i.v. (100 min) on days 1 and 8 (arm B)
Study: 11915854
Drug: Alora 0.1
Normalized name: Alora 0.1mg/24hr Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alora 0.1 mg/day
Study: 11915854
Drug: Alora 0.05
Normalized name: Alora 0.05mg/24hr Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alora 0.05 mg/day
Study: 11915854
Drug: CEE 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 1.25 mg/day
Study: 7718674
Drug: Clomipramine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (12.5 mg, i.v.)
Study: 2167788
Drug: Aspirin infusion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin infusion at 1 mumol/l
Study: 2167788
Drug: Aspirin infusion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin infusion at 2 mumol/l
Study: 2167788
Drug: Aspirin infusion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin infusion at 4 mumol/l
Study: 2167788
Drug: Aspirin infusion
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin infusion at 0 mumol/l (control)
Study: 7232461
Drug: Secobarbital (30-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secobarbital (30-300 mg)
Study: 7232461
Drug: Chlorpromazine (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (25-100 mg)
Study: 22736123
Drug: Individualized fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized fluid therapy
Study: 18525035
Drug: Control regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control regimen (single‐dose nevirapine plus 1 week of zidovudine)
Study: 12079630
Drug: 1.45 microm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.45 microm diode laser treatment with an average power of 12 W, heating times from 150 ms to 500 ms, applied over two to six treatment cycles.
Study: 7564350
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg quinapril plus 12.5 mg hydrochlorothiazide (HCTZ)
Study: 7564350
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg quinapril monotherapy
Study: 7564350
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hydrochlorothiazide (HCTZ) monotherapy
Study: 7564350
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (quinapril + HCTZ)
Study: 2209135
Drug: Bendrofluazide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide plus triamterene 200 mg
Study: 2209135
Drug: Bendrofluazide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide plus spironolactone 100 mg
Study: 2209135
Drug: Bendrofluazide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide plus triamterene 50 mg
Study: 2209135
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose triamterene
Study: 7188585
Drug: Prizidilol (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol (400-800 mg/day)
Study: 7188585
Drug: Prizidilol (mean:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol (mean: 447 mg once daily)
Study: 7188585
Drug: Prizidilol (mean:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol (mean: 700 mg once daily)
Study: 31117809
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) sinus implant (1350 mcg) and MF nasal spray (MFNS)
Study: 31117809
Drug: MF nasal
Normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF nasal spray (MFNS) alone
Study: 29072002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with oral loxoprofen sodium tablets (60 mg, twice a day, for one week)
Study: 29072002
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups showed significant decrease in ROM and VAS scores post-treatment (P<0.01)
Study: 23941282
Drug: Modified balloon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified balloon dilatation treatment and regular dysphagia therapy
Study: 23941282
Drug: Regular dysphagia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dysphagia therapy only
Study: 19835591
Drug: Alternative medication
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative medication (BTA or saline) for non-responders in subgroups C and D
Study: 14964681
Drug: Prompt‐L‐Pop (PLP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt‐L‐Pop (PLP)
Study: 6239300
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Haloperidol (0.014 mg/kg IM)
Study: 6239300
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Propranolol (0.1 mg/kg IV)
Study: 6239300
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Thymoxamine (0.1 mg/kg IV)
Study: 6239300
Drug: Dextroamphetamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (0.3 mg/kg IV) with Placebo
Study: 27206564
Drug: Fentanyl iontophoretic
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS)
Study: 27206564
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia morphine (IV PCA morphine)
Study: 23026438
Drug: Umeclidinium 250
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium 250 μg
Study: 23026438
Drug: Umeclidinium 500
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium 500 μg
Study: 16887429
Drug: Neridronate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate treatment (2 mg/kg administered intravenously for 2 consecutive days, every 3 months)
Study: 14962524
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (16 mmol over 15 min and then 65 mmol over 24 h)
Study: 11298538
Drug: 0.2% SDZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% SDZ ASM 981 cream
Study: 11298538
Drug: 0.6% SDZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% SDZ ASM 981 cream
Study: 11298538
Drug: 1.0% SDZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% SDZ ASM 981 cream
Study: 11298538
Drug: 0.1% betamethasone-17-valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone-17-valerate cream (BMV)
Study: 9613279
Drug: Whoosh test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whoosh test (injection of air into the caudal epidural space)
Study: 7924125
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day cetirizine
Study: 7924125
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day cetirizine
Study: 1100055
Drug: Catalase (Optidase)
Normalized name: catalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catalase (Optidase) injections
Study: 1100055
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without catalase
Study: 1100055
Drug: Catalase (Optidase)
Normalized name: catalase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catalase (Optidase) injections in extended study
Study: 16836774
Drug: Child-friendly constraint-induced
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-friendly constraint-induced movement therapy (CI therapy); 6 hours per day for 10 out of 12 consecutive days
Study: 16836774
Drug: Child-friendly constraint-induced
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child-friendly constraint-induced movement therapy (CI therapy)
Study: 12015761
Drug: THP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: THP (30 mg/30 mL of normal saline) administered into the bladder within 6 hours after TUR‐Bt
Study: 11382659
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg/d)